Carbapenems are relatively expensive, second or third line antibiotics which are used in infections caused by antibiotic resistant bacteria. However, results from the Resistance Map project conducted by the Center for Disease Dynamics, Economics and Policy (CDDEP) has shown that the use of carbapenems is on the rise in India, mainly driven by rampant prescribing in healthcare settings accompanied by ready, over-the-counter availability without prescriptions or with invalid prescriptions. Given this rise in the consumption of carbapenems, it is logical to hypothesise that the number of carbapenem resistant bacterial infections should be on the rise. In fact, in the developed world, Carbapenem Resistant Enterobacteriaceae have become a major source of concern. In India, although the proportion of samples reported to bear Carbapenem Resistant Escherichia coli has remained relatively stable over the past decade or so, there has been a distressing rise in the proportion of Carbapenem Resistant Klebsiella. Given this scenario, an interesting study has come out in a recent issue of the CDC’s Emerging Infectious Diseases journal that talks about carbapenem resistance in a bacterial genus which has not been in the resistance discourse – Vibrio.